GLPG

Galapagos NV
GLPG

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
€1.82B
EV
€-1.27B
Shares Outstanding
65.93M
Beta
-0.05

Wall Street View

Analyst Rating
HOLD
Analyst Target Price
€30.26
P/E 2025E
-
P/Revenue 2025E
6.48x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Galapagos NV

gainify
GLPG

Galapagos NV

GLPG

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manuf...

Sector

Healthcare

Industry

Biotechnology

CEO

Stoffels, Paulus

Employees

558

IPO Date

2005-05-06

Headquarters

Generaal De Wittelaan L11 A3, Mechelen, Antwerp, 2800, Belgium

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.